×
Request Free Sample ×
Myasthenia Gravis Market Research Report – Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Myasthenia Gravis Market

ID: MRFR/HC/5800-CR
200 Pages
Rahul Gotadki
December 2024

Myasthenia Gravis Market Research Report By Disease Type (Acetylcholine Receptor Antibody Positive Myasthenia Gravis, Muscle-Specific Kinase Antibody Positive Myasthenia Gravis, Seronegative Myasthenia Gravis), By Treatment Type (Anticholinesterase Agents, Immunosuppressants, Intravenous Immunoglobulin, Plasmapheresis, Thymectomy), By Route of Administration (Oral, Intravenous, Subcutaneous), By End User (Hospitals, Specialty Clinics, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Afri... read more

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Myasthenia Gravis Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Myasthenia Gravis Market Summary

As per MRFR analysis, the Myasthenia Gravis Market Size was estimated at 1395.16 USD Million in 2024. The Myasthenia Gravis industry is projected to grow from 1497.29 USD Million in 2025 to 3034.75 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 7.32 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Myasthenia Gravis market is poised for growth driven by innovative therapies and increasing patient awareness.

  • The emergence of novel therapies is reshaping treatment paradigms in the Myasthenia Gravis market.
  • North America remains the largest market, while Asia-Pacific is recognized as the fastest-growing region.
  • Anticholinesterase inhibitors dominate the market, whereas monoclonal antibodies are experiencing rapid growth.
  • Rising incidence of Myasthenia Gravis and advancements in research and development are key drivers fueling market expansion.

Market Size & Forecast

2024 Market Size 1395.16 (USD Million)
2035 Market Size 3034.75 (USD Million)
CAGR (2025 - 2035) 7.32%

Major Players

Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB)

Myasthenia Gravis Market Trends

The Myasthenia Gravis Market is currently experiencing notable developments driven by advancements in treatment options and increased awareness of the condition. As healthcare professionals and researchers delve deeper into the complexities of this autoimmune disorder, innovative therapies are emerging, which may enhance patient outcomes. The growing understanding of the underlying mechanisms of Myasthenia Gravis is likely to foster the development of targeted therapies, potentially transforming the treatment landscape. Furthermore, the rising prevalence of this condition is prompting healthcare systems to allocate more resources towards research and patient care, indicating a shift in focus towards improving quality of life for affected individuals. In addition, the Myasthenia Gravis Market appears to be influenced by collaborative efforts among pharmaceutical companies, academic institutions, and patient advocacy groups. These partnerships may facilitate the sharing of knowledge and resources, ultimately leading to more effective treatment strategies. The increasing emphasis on personalized medicine suggests that future therapies could be tailored to individual patient profiles, enhancing efficacy and minimizing side effects. Overall, the Myasthenia Gravis Market is poised for growth, driven by innovation, collaboration, and a commitment to improving patient care.

Emergence of Novel Therapies

The Myasthenia Gravis Market is witnessing the introduction of innovative treatment modalities that target specific pathways involved in the disease. These novel therapies may offer improved efficacy and safety profiles compared to traditional options, potentially reshaping the therapeutic landscape.

Increased Patient Awareness

There is a growing awareness among patients and healthcare providers regarding Myasthenia Gravis, which may lead to earlier diagnosis and intervention. This heightened awareness could contribute to an increase in demand for treatment options and support services.

Focus on Personalized Medicine

The trend towards personalized medicine is becoming more pronounced within the Myasthenia Gravis Market. Tailoring treatments to individual patient characteristics may enhance therapeutic outcomes and reduce adverse effects, reflecting a shift towards more patient-centered care.

Myasthenia Gravis Market Drivers

Increasing Prevalence of Myasthenia Gravis

The Global Myasthenia Gravis Market Industry is witnessing a notable increase in the prevalence of myasthenia gravis, a chronic autoimmune disorder characterized by weakness in the skeletal muscles. Current estimates suggest that the incidence rate is approximately 20 cases per 100,000 people, with a higher prevalence observed in women, particularly those aged 20 to 40. This rising incidence is likely to drive demand for innovative therapies and treatment options, contributing to the market's growth. As the population ages, the number of individuals affected by this condition is expected to rise, further emphasizing the need for effective management strategies within the Global Myasthenia Gravis Market Industry.

Market Segment Insights

By Treatment Type: Anticholinesterase Inhibitors (Largest) vs. Monoclonal Antibodies (Fastest-Growing)

The treatment landscape for Myasthenia Gravis is characterized by a diverse range of options, with Anticholinesterase Inhibitors holding the largest market share due to their extensive use in symptomatic relief for patients. The segment also includes Immunosuppressants, Plasmapheresis, and Intravenous Immunoglobulin, which cater to different therapeutic needs. Anticholinesterase Inhibitors are widely adopted, resulting in a stable demand that significantly influences market dynamics. In terms of growth trends, Monoclonal Antibodies emerged as the fastest-growing treatment type, driven by advancements in biotechnology and a growing understanding of the immune mechanisms underlying Myasthenia Gravis. This growth reflects the increasing preference for targeted therapies, which offer improved efficacy and safety profiles compared to traditional treatment options. The rising incidence of Myasthenia Gravis further propels the demand for innovative treatment solutions, making this segment an area of intense research and investment.

Anticholinesterase Inhibitors (Dominant) vs. Monoclonal Antibodies (Emerging)

Anticholinesterase Inhibitors represent the dominant treatment modality in the Myasthenia Gravis market, primarily utilized for enhancing neuromuscular transmission and alleviating muscle weakness. These agents have established a long-standing presence due to their effectiveness and the familiarity of healthcare practitioners with their use. Conversely, Monoclonal Antibodies are an emerging segment, showcasing innovation in targeted therapy for Myasthenia Gravis. These therapies aim to modify specific pathways involved in the disease process, showing promising efficacy in clinical trials. The increasing focus on personalized medicine and the continuous research efforts enhance the potential of Monoclonal Antibodies to reshape the therapeutic landscape, attracting attention from both clinicians and patients seeking advanced treatment options.

By Disease Severity: Severe (Largest) vs. Moderate (Fastest-Growing)

In the Myasthenia Gravis Market, the distribution of disease severity segments reveals that Severe cases dominate the market landscape, accounting for the largest share. This segment's prominence is attributed to the heightened medical requirement for therapies and management options suited for patients experiencing significant symptoms. Following this, Moderate disease severity showcases a rapidly increasing market presence, driven by the rising awareness of Myasthenia Gravis and its treatment options among both healthcare providers and patients, contributing to the expansion of this segment.

Moderate (Dominant) vs. Crisis (Emerging)

The Moderate disease severity segment holds a dominant position in the Myasthenia Gravis Market, characterized by manageable yet impactful symptoms that necessitate ongoing treatment and monitoring. This segment sees substantial patient engagement due to the balance of severity, which allows for a variety of treatment options to be explored. In contrast, the Crisis segment is emerging as a noteworthy category as awareness increases regarding acute exacerbation episodes that require immediate medical attention. This growing recognition heralds potential innovations in treatment protocols and care strategies that address the urgent needs of Crisis patients while enhancing overall disease management.

By Patient Demographics: Age (Largest) vs. Gender (Fastest-Growing)

In the Myasthenia Gravis market, the patient demographics segment exhibits notable variations in age distribution and gender prevalence. The largest segment is composed of older adults, particularly those aged 50 and above, who represent a significant portion of diagnosed patients. This age group is particularly vulnerable to auto-immune disorders, such as Myasthenia Gravis, leading to their substantial share in the market. Parallelly, gender differences are notable, with women being diagnosed more frequently than men, although the male population shows a faster growth rate in diagnosis. This trend points toward increased awareness and recognition of Myasthenia Gravis in males, alongside evolving demographics in healthcare access and health-seeking behavior among different genders.

Age (Dominant) vs. Gender (Emerging)

The age demographic remains dominant in the Myasthenia Gravis market, as older adults continue to represent the majority of patients diagnosed with this condition due to age-related susceptibility to auto-immune diseases. Furthermore, health initiatives targeting aging populations have increased awareness and understanding of Myasthenia Gravis among older adults. On the other hand, gender represents an emerging segment in this market, as an increasing number of male patients are being diagnosed, attributed to greater awareness, social factors, and a shift towards proactive health management among men. This evolving landscape highlights the importance of tailored healthcare strategies that address the unique needs of these demographics.

By Administration Route: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

In the Myasthenia Gravis market, the administration route segment showcases a diverse range of options, with intravenous (IV) administration leading in market share. This dominance is primarily due to the rapid onset of action and the ability to deliver larger doses, catering to severe cases effectively. Subsequent options like oral and subcutaneous routes are also significant, but they cater to specific patient preferences and clinical scenarios, which can influence their market impact. Furthermore, subcutaneous administration is gaining traction, being favored for its user-friendly nature and convenience, especially among patients seeking at-home treatment options.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

The intravenous administration route remains the dominant choice for delivering treatments in the Myasthenia Gravis market, primarily due to its efficiency in drug absorption and immediate therapeutic effect. It is particularly suited for acute management, where quick action is necessary. In contrast, the subcutaneous route is emerging as a favorable alternative, appealing to patients looking for convenience and reduced frequency of hospital visits. Subcutaneous treatments allow for at-home administration, thereby enhancing patient compliance and comfort. Both routes present unique benefits, with intravenous therapy being a staple for acute episodes, while subcutaneous therapies pave the way for chronic management.

By Healthcare Setting: Hospital (Largest) vs. Outpatient Clinic (Fastest-Growing)

In the Myasthenia Gravis market, the healthcare setting segment distribution reflects a diverse landscape, where Hospitals hold the largest share due to their comprehensive service capacity and advanced treatment modalities. They provide specialized care with robust resources, making them the preferred choice for severe Myasthenia Gravis cases. In contrast, Outpatient Clinics are witnessing rapid growth as they offer accessibility and convenience, catering to a rising number of patients who prefer receiving care without the need for hospitalization. This shift towards outpatient services highlights the changing preferences among patients and healthcare providers alike.

Healthcare Setting: Hospital (Dominant) vs. Outpatient Clinic (Emerging)

Hospitals serve as the dominant setting for Myasthenia Gravis management, equipped with specialized teams that can address complex cases, including providing emergency interventions when necessary. Additionally, they often facilitate clinical trials, contributing to advancements in treatment options. On the other hand, Outpatient Clinics are emerging as a vital component of the healthcare ecosystem, offering personalized care plans and follow-up treatments for patients who manage their condition more stably. They focus on patient education and medication management, which are crucial in the chronic management of Myasthenia Gravis, thus making them increasingly attractive to both patients and providers.

Get more detailed insights about Myasthenia Gravis Market
Request Free Sample

Regional Insights

North America : Market Leader in Myasthenia Gravis

North America is poised to maintain its leadership in the Myasthenia Gravis market, holding a significant market share of $700.0M in 2024. The region's growth is driven by increasing prevalence rates, advancements in treatment options, and supportive regulatory frameworks. The demand for innovative therapies is further fueled by rising awareness and improved diagnostic capabilities, making it a key player in the global landscape. The competitive landscape in North America is characterized by the presence of major pharmaceutical companies such as Roche, Bristol-Myers Squibb, and Pfizer. These companies are actively engaged in research and development to introduce novel therapies. The U.S. remains the leading country, supported by a robust healthcare infrastructure and favorable reimbursement policies, ensuring continued investment in Myasthenia Gravis treatments.

Europe : Emerging Market with Growth Potential

Europe is witnessing a growing Myasthenia Gravis market, valued at $400.0M in 2024. The region benefits from a strong regulatory environment that encourages innovation and access to new therapies. Increased awareness and early diagnosis are driving demand, alongside a rise in clinical trials aimed at developing effective treatments. The European Medicines Agency (EMA) plays a crucial role in facilitating market entry for new drugs, enhancing patient access to therapies. Leading countries in Europe include Germany, France, and the UK, where healthcare systems are increasingly prioritizing neuromuscular disorders. Key players like Novartis and Sanofi are investing in research to expand their portfolios. The competitive landscape is evolving, with a focus on personalized medicine and biologics, positioning Europe as a significant player in the Myasthenia Gravis market.

Asia-Pacific : Growing Market with Untapped Potential

The Asia-Pacific region is emerging as a significant player in the Myasthenia Gravis market, currently valued at $250.0M in 2024. Factors such as increasing healthcare expenditure, rising awareness of neuromuscular disorders, and a growing aging population are driving market growth. Regulatory bodies are also becoming more supportive of new drug approvals, which is crucial for expanding treatment options in this region. Countries like Japan, China, and Australia are leading the charge, with a growing number of clinical trials and research initiatives. Key players such as Eisai and Amgen are focusing on developing innovative therapies tailored to the needs of the region. The competitive landscape is evolving, with an emphasis on collaboration between pharmaceutical companies and healthcare providers to enhance patient outcomes and access to treatments.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region represents a nascent market for Myasthenia Gravis, valued at $45.16M in 2024. The growth is hindered by limited healthcare infrastructure and awareness of the disease. However, increasing investment in healthcare and initiatives to improve access to treatments are beginning to change the landscape. Regulatory bodies are working to streamline processes for drug approvals, which is essential for market growth. Countries like South Africa and the UAE are at the forefront, with efforts to enhance healthcare services and patient education. The presence of global players is limited, but companies are starting to explore opportunities in this region. The competitive landscape is gradually evolving, with a focus on partnerships and collaborations to address the unique challenges faced in the Middle East and Africa.

Key Players and Competitive Insights

The Myasthenia Gravis Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Novartis (CH) are actively shaping the market through strategic initiatives focused on research and development, partnerships, and regional expansion. Roche (CH) emphasizes innovation in biologics, while Bristol-Myers Squibb (US) leverages its extensive oncology portfolio to explore synergies in autoimmune disorders. Novartis (CH) is concentrating on expanding its pipeline of neuromuscular therapies, indicating a collective shift towards targeted treatment options that enhance patient outcomes.

In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The competitive structure of the Myasthenia Gravis Market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set the pace for innovation and market trends, thereby shaping the overall competitive environment.

In November 2025, Roche (CH) announced a strategic partnership with a leading biotechnology firm to co-develop a novel monoclonal antibody aimed at treating Myasthenia Gravis. This collaboration is expected to enhance Roche's research capabilities and accelerate the development timeline for new therapies, positioning the company as a frontrunner in the market. The strategic importance of this partnership lies in its potential to leverage cutting-edge technology and expertise, thereby improving treatment options for patients.

In October 2025, Bristol-Myers Squibb (US) launched a new clinical trial for its investigational therapy targeting Myasthenia Gravis, which aims to assess the efficacy of a combination treatment approach. This move underscores the company's commitment to advancing treatment paradigms and reflects a broader trend towards personalized medicine. The trial's outcomes could significantly influence treatment guidelines and establish Bristol-Myers Squibb as a key player in the therapeutic landscape.

In September 2025, Novartis (CH) expanded its global footprint by entering into a licensing agreement with a European firm to distribute its Myasthenia Gravis treatment in new markets. This strategic action not only enhances Novartis's market access but also aligns with its goal of increasing patient access to innovative therapies. The implications of this agreement may lead to a stronger competitive position in emerging markets, where demand for effective treatments is on the rise.

As of December 2025, current competitive trends in the Myasthenia Gravis Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming pivotal in shaping the landscape, as companies collaborate to enhance their research capabilities and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, thereby fostering a more resilient and responsive market environment.

Key Companies in the Myasthenia Gravis Market market include

Industry Developments

  • Q4 2024: UCB receives FDA approval for ZILBRYSQ (zilucoplan) for generalized myasthenia gravis in adults UCB announced that the U.S. FDA approved ZILBRYSQ (zilucoplan), a once-daily subcutaneous peptide inhibitor, for the treatment of generalized myasthenia gravis in adult patients, marking a significant regulatory milestone for the company.
  • Q2 2024: Argenx receives European Commission approval for Vyvgart for generalized myasthenia gravis Argenx secured European Commission approval for its drug Vyvgart (efgartigimod alfa) for the treatment of generalized myasthenia gravis, expanding its market presence in Europe.
  • Q1 2024: Alexion, AstraZeneca Rare Disease, announces positive Phase 3 results for Ultomiris in myasthenia gravis Alexion, AstraZeneca Rare Disease, reported positive Phase 3 clinical trial results for Ultomiris (ravulizumab) in patients with generalized myasthenia gravis, paving the way for potential regulatory submissions.
  • Q2 2024: UCB partners with Roche to co-develop new monoclonal antibody for myasthenia gravis UCB and Roche announced a strategic partnership to co-develop a next-generation monoclonal antibody targeting refractory myasthenia gravis, aiming to address unmet clinical needs.
  • Q3 2024: Argenx raises $400 million in public offering to expand myasthenia gravis drug portfolio Argenx completed a $400 million public offering to support the expansion of its myasthenia gravis drug portfolio and fund ongoing clinical trials.
  • Q2 2025: Descartes-08 receives FDA Fast Track designation for myasthenia gravis Descartes-08, a novel RNA-engineered cell therapy, was granted Fast Track designation by the FDA for the treatment of generalized myasthenia gravis, accelerating its development timeline.
  • Q1 2025: AstraZeneca opens new manufacturing facility for myasthenia gravis biologics in the US AstraZeneca inaugurated a new state-of-the-art manufacturing facility in the United States dedicated to producing biologics for rare diseases, including myasthenia gravis.
  • Q2 2024: Immunovant announces $230 million Series C funding to advance anti-FcRn antibody for myasthenia gravis Immunovant raised $230 million in Series C funding to accelerate the development of its anti-FcRn antibody, IMVT-1402, for the treatment of myasthenia gravis.
  • Q3 2024: Janssen submits BLA to FDA for nipocalimab in generalized myasthenia gravis Janssen, a Johnson & Johnson company, submitted a Biologics License Application (BLA) to the FDA for nipocalimab, a monoclonal antibody for the treatment of generalized myasthenia gravis.
  • Q2 2025: Telitacicept receives conditional approval in China for myasthenia gravis Telitacicept, developed by RemeGen, received conditional approval from Chinese regulators for the treatment of myasthenia gravis, marking its first market entry.
  • Q1 2025: UCB appoints new Head of Rare Disease Division to lead myasthenia gravis strategy UCB announced the appointment of a new Head of Rare Disease Division to oversee its global strategy for myasthenia gravis and other rare autoimmune disorders.
  • Q4 2024: CRD-1 initiates Phase 2 trial for seronegative myasthenia gravis patients CRD-1, a novel therapeutic candidate, began Phase 2 clinical trials targeting seronegative myasthenia gravis patients, addressing a significant unmet need in the market.

Future Outlook

Myasthenia Gravis Market Future Outlook

The Myasthenia Gravis Market is projected to grow at a 7.32% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing awareness.

New opportunities lie in:

  • Development of targeted biologics for personalized treatment plans.
  • Expansion of telehealth services for remote patient monitoring.
  • Investment in AI-driven diagnostic tools for early detection.

By 2035, the Myasthenia Gravis Market is expected to achieve substantial growth and innovation.

Market Segmentation

Myasthenia Gravis Market Treatment Type Outlook

  • Anticholinesterase Inhibitors
  • Immunosuppressants
  • Monoclonal Antibodies
  • Plasmapheresis
  • Intravenous Immunoglobulin

Myasthenia Gravis Market Disease Severity Outlook

  • Mild
  • Moderate
  • Severe
  • Crisis
  • Asymptomatic

Myasthenia Gravis Market Healthcare Setting Outlook

  • Hospital
  • Outpatient Clinic
  • Home Healthcare
  • Long-term Care Facility
  • Specialized Treatment Center

Myasthenia Gravis Market Administration Route Outlook

  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Topical

Myasthenia Gravis Market Patient Demographics Outlook

  • Age
  • Gender
  • Ethnicity
  • Socioeconomic Status
  • Geographic Distribution

Report Scope

MARKET SIZE 20241395.16(USD Million)
MARKET SIZE 20251497.29(USD Million)
MARKET SIZE 20353034.75(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)7.32% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledRoche (CH), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB)
Segments CoveredTreatment Type, Disease Severity, Patient Demographics, Administration Route, Healthcare Setting
Key Market OpportunitiesAdvancements in targeted therapies and personalized medicine enhance treatment options in the Myasthenia Gravis Market.
Key Market DynamicsRising demand for innovative therapies drives competitive dynamics in the Myasthenia Gravis market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

Market Highlights

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is the projected growth of the Myasthenia Gravis market?

The Myasthenia Gravis market is the expected increase in total market value of 3.03 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Myasthenia Gravis market?

Myasthenia Gravis market size was valued at approximately 1.4 billion USD in 2024. This figure will reach 3.03 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Myasthenia Gravis market?

Myasthenia Gravis market is expected to grow at a CAGR of 7.32% between 2025 and 2035.

How much will the Myasthenia Gravis market be worth by 2035?

Myasthenia Gravis market is expected to be worth of 3.03 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Myasthenia Gravis market perform over the next 10 years?

Over the next 10 years the Myasthenia Gravis market is expected to shift from usd billion 1.4 to 3.03 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What is the total expected value of the Global Myasthenia Gravis Market in 2024?

The Global Myasthenia Gravis Market is expected to be valued at 2.11 USD Billion in 2024.

Which region holds the largest market share in the Global Myasthenia Gravis Market in 2024?

North America holds the largest market share with a value of 0.9 USD Billion in 2024.

What is the estimated market value for Europe in the Global Myasthenia Gravis Market by 2035?

The estimated market value for Europe is projected to be 1.4 USD Billion by 2035.

What market size is anticipated for Acetylcholine Receptor Antibody Positive Myasthenia Gravis in 2024?

The market size for Acetylcholine Receptor Antibody Positive Myasthenia Gravis is expected to be 0.87 USD Billion in 2024.

Who are the key players in the Global Myasthenia Gravis Market?

Key players include Pfizer, Merck & Co, Roche, Johnson & Johnson, and UCB among others.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓